Estudio de pacientes diagnosticados con Leucemia Mielógena Crónica tratados con STI 571 (Gleevec) en Ecuador
Main Article Content
Abstract
The main marker of Chronic Myeloid Leukemia (CML) is considered to be the translocation t(9;22) or Ph chromosome, which occurs in 90-95% of patients with CML. One of the most effective treatments is Gleevec whose target is Ph positive cells. An advantage of this new drug is the differentiation between normal and abnormal cells, and the induction of apoptosis. Thirty-one patients were studied: 13 in chronic phase, 12 in accelerated phase, and 6 in blast crisis over 1 year. Hematological remission was obtained in all cases of chronic phase, but approximately 50% of patients in accelerated phase and blast crisis responded. Cytogenetic remission occurred in 79% of the chronic phase and varied from 17 to 32% in the accelerated phase and blast crisis. There was no molecular remission in any patient. Genetic analysis is a good tool to determine the efficacy of treatment and monitoring of leukemia cases.
Downloads
Article Details
References
BUCHDUNGER, E.; MATTER, A. & DRUKER, B. J. 2001. Bcr-Abl inhibítion as a modality of CML therapeutieso Bioehim Biophys Acta; 1551:M1I M18.
MAURO, M. J. & DRUKER, B. J. 2001. STI571: Targeting BCR-ABL as therapy for CML. Oneologist; 6:233-238.
DRUKER, B. J.; TALPAZ, M.; RESTA, D. J.; BIN-PENG, R. N.; BUCH DUNGER, E.; FORD, J. M.; LYDON, N. B.; KANTARJIAN, H.; CAPDEVILLE, R.; OHNO-JONES, S. & SAWYERS. 2001. Efficaey and safety inhibitor of the BCR-ABL tyrosine kinase in chronic myeIoid leukemia. D New Engl J Med, 344:1031-1037.
DOBROVIC, A.; MORLEY, A. A.; SESHADRl, R. & JANUSZEWICZ, E. H. 1991. Molecular diagnosis of philadelphia negative CML using the polymerase chain reaction and DNA analysis: clínical features and course of Mbcr negative and M-ber positíve CML. Leukemia, 5:187-190.
CORTES, J. E.; TALPAZ, M.; BERAN, M.; O'BRIEN, S. M.; RIOS, M. B. & KANTARJIAN, H. M. 1995. Philadelphia chromosome. Negative Chronic Myelogenous Leukemia with rearrangement of the breakpoint cluster region. Cancer, 75:434-469.
YAISH, P.; GAZIT, A. & GILON, C. 1988. Blocking ofEGF~dependent cell proliferation by EGF receptor kinase inhibitors. Science, 242:933-935.
PAZ Y MIÑO, c.; BURGOS, R.; MORILLO, S. A.; SANTOS, 1. c.; FIALLO, B. F. & LEONE, P. E. 2002. BCR-ABL rearrangement frequencies in chronic myeloid leukemia and acute lymphoblastic leukemia in Ecuador. Cancer Genel Cylogen;123, 65-67.